Related Experiment Videos
Immunologic cross-reactivity of antigen(s) induced by drug treatment in two leukemic sublines
Abstract:
Previous studies have demonstrated that new antigenic specificities, not detectable on parental cells, can be induced by in vivo treatment of murine leukemic cells with anti-neoplastic agents. The immunologic properties of leukemic cells altered by treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DIC) were investigated further. Immunologic cross-reactivity between two DIC-treated leukemic sublines has been demonstrated by cell-mediated immunity in vitro and by active or adoptive immunity in vivo. Rabbit antiserum to DIC-treated sublines absorbed with the parental cells showed residual activity against the DIC-sublines that was specifically inhibited by further absorption with DIC-cells.
Insights
Treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DIC) induced new antigenic specificities on murine leukemic cells. These altered cells showed immunologic cross-reactivity, indicating potential for novel cancer immunotherapies.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- * Antineoplastic agents can induce new antigenic specificities on leukemic cells.
- * Investigating these altered immunologic properties is crucial for understanding treatment effects.
Purpose of the Study:
- * To investigate the immunologic properties of leukemic cells treated with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DIC).
- * To demonstrate immunologic cross-reactivity between DIC-treated leukemic sublines.
Main Methods:
- * In vitro cell-mediated immunity assays.
- * In vivo active and adoptive immunity studies.
- * Antiserum absorption experiments using parental and DIC-treated cells.
Main Results:
- * Immunologic cross-reactivity was demonstrated between two DIC-treated leukemic sublines.
- * Rabbit antiserum against DIC-treated cells, when absorbed with parental cells, retained activity against DIC-sublines.
- * This residual activity was specifically inhibited by further absorption with DIC-treated cells.
Conclusions:
- * Treatment with DIC induces unique antigenic specificities on murine leukemic cells.
- * These induced specificities mediate immunologic cross-reactivity between altered leukemic cell populations.
- * Findings suggest potential for developing targeted immunotherapies against cancer cells exhibiting DIC-induced antigens.